Dr. Andrews and his team have conducted scientific exploration into IntelliCell BioSciences’ technology with professional athletes and seen positive results. The two groups are also discussing the possibility of establishing an IntelliCell Center of Excellence at the Andrews Institute to conduct clinical research in the use of stormal vascular fracture cells manufactured with the company’s proprietary non-enzymatic process.
Related Articles on Orthopedic Devices:
Exactech Begins Trial for Cartilage Repair Technology
Biomet Reports 2Q Net Sales Increase, but Spine Sales Down 5%
MedShape Receives Patent for Memory Technology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.